Drug Trial Radar · NCT00456963
Prevention of Diabetes and Hypertension
Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3,000
Planned (sponsor's estimate)
Start
Sep 2007
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- Istituto Auxologico ItalianoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Italian Society of Hypertension; Italian Society of General Practitioners; Yghea
- First posted
- Apr 5, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background. Antihypertensive therapy with ß-blockers (ßBs) and diureticts (Ds) is accompanied by a higher incidence of diabetes mellitus (DM) than therapy with ACE-inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs). Whether this difference is due to an antidiabetogenic action of ACEIs and ARBs or to the fact that these agents are free of the diabetogenic activity of ßBs and Ds is unknown. Prevention of DM as well as of HT is of primary health concern. Objectives. The primary objective of PHIDIAS is to test whether in individuals with components of metabolic syndrome making them predisposed to DM and HT, addition of either an ACEI or an ARB to periodically reinforced lifestyle counselling can reduce 1) onset of DM and 2) onset of HT significantly more than lifestyle plus placebo. Secondary objectives are 1) comparing the antidiabetogenic effects of ACEI and ARB, and 2) investigating whether the effects of ACEI and ARB on DM and HT persist at least 6 months after treatment withdrawal. Methods. PHIDIAS is a prospective, double-blind, placebo-controlled 3-arm comparison trial. 300 general practitioners (members of SIMG with the assistance of hospital centres of SIIA) will randomise 6000 untreated individuals aged 40-75 years, with SBP 130-139 or DBP 85-89 mmHg, fasting glucose (FG) 100-125 mg/dl, waist circumference \>= 102 (M) or \>= 88 cm (W), to three blinded treatments, given in addition to lifestyle advise: 1) Placebo; 2) the ACE Enalapril (10 mg, then 20 mg od); 3) the ARB Losartan (50 mg, then 100 mg od).Double-blind treatment will be maintained until 500 cases of DM are observed (presumably average of 36 months) (Treatment Phase: control visits, BP, FG every 6 months). This will be followed by a 6-month Withdrawal Phase (active treatment substituted by placebo). Primary outcomes are DM (FG \>= 126 mg/dl) and HT (SBP \>= 140 or DBP \>= 90 mmHg) on 2 consecutive visits. PHIDIAS will be governed by a Steering Committee assisted by a blinded Event Adjudicating Committee and an independent DMSB. Expected results. The sample size is adequate (alfa 5%, power 90%) to evaluate whether incident DM (expected rate 3.5%/year) or incident HT is reduced 25% by ACEI and ARB versus placebo (primary hypothesis) and whether either the ACEI or the ARB reduces incident DM by 30% more than the other agent.
Conditions
- Diabetes Mellitus
- Hypertension
Interventions
DietBehavioral
total fat \< 5%, saturated fat \< 10%, vegetables, fruit
Moderate exerciseBehavioral
30 min at least 5 times/week
enalapril tabletsDrug
one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
placebo tabletsDrug
one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
Losartan TabletsDrug
one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first event of: new diabetes or initiation of any antidiabetic treatment during the treatment period of the trial
- new hypertension or initiation of any antihypertensive treatment during the treatment period of the trial.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituto Auxologico Italiano.
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.